Epidemiology, Clinical Characteristics, Risk Factors, and Outcomes of Candidemia in a Large Tertiary Teaching Hospital in Western China: A Retrospective 5-Year Study from 2016 to 2020.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 14 citations in OpenAlex.

1. The Pyrazolone Scaffold: A Privileged Motif for Molecular Hybridization in Drug Discovery.ChemMedChem · 2026
   Review
2. [Rapid detection of fluconazole resistance inNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
   Article
3. Clinical characteristics and risk factors of mortality in patients with candidemia: a four-year retrospective study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
   Article
4. Epidemiology, Antifungal Susceptibility, and in-Hospital Mortality of Candidemia in a Tertiary Hospital of China: A 10-Year Retrospective Analysis.Infection and drug resistance · 2026
   Article
5. Blood Stream Infections due toInternational journal of microbiology · 2026
   Article
6. [Molecular Epidemiology and Fluconazole Resistance Mechanisms inSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025
   Article
7. Epidemiology, risk factors, and antifungal susceptibility analysis of Candida tropicalis and non-C.tropicalis candidemia.BMC infectious diseases · 2025
   Article
8. Eicosapentaenoic acid as an antibiofilm agent disrupts mature biofilms ofBiofilm · 2025
   Article
9. Epidemiology, clinical characteristics, and outcome in candidemia: a retrospective five-year analysis from two tertiary general hospitals.BMC infectious diseases · 2025
   Observational
10. Research advances and public health strategies in China on WHO priority fungal pathogens.Mycology · 2025
    Review
11. Candidemia chronicles: Retrospective analysis of candidemia epidemiology, species distribution, and antifungal susceptibility patterns in Bahrain.World journal of virology · 2024
    Article
12. Alarming Increase of Azole-Resistant Candida Causing Blood Stream Infections in Oncology Patients in Egypt.Current microbiology · 2023
    Article
13. Six-Year Retrospective Analysis of Epidemiology, Risk Factors, and Antifungal Susceptibilities of Candidiasis from a Tertiary Care Hospital in South China.Microbiology spectrum · 2023
    Article
14. Hesperetin-Between the Ability to Diminish Mono- and Polymicrobial Biofilms and Toxicity.Molecules (Basel, Switzerland) · 2022
    Article
15. Development and validation of a sensitive LC-MS/MS method for determination of intracellular concentration of fluconazole inFrontiers in microbiology · 2022
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

8 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as